Abstract
Mesenchymal Stromal Cells In article number 2200431, Wenjun Yan, Ling Tao, and co-workers report a novel strategy for improving the curative effect of mesenchymal stromal cell (MSC)-based therapy for myocardial infarction that is achieved by bile acid- arnesoid X receptor (FXR) axis activation. FXR overexpression in MSC facilitates the response of MSC to endogenous bile acid signals, thus enhancing the survival and paracrine angiogenesis of MSC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
